AbbVie Reports Third-Quarter 2026 Financial Results

AbbVie reported its third-quarter 2026 financial results on 30 October 2026.

Chief Executive Officer Robert A. Michael pointed to broad-based momentum during an investor conference call hosted from corporate headquarters.

"AbbVie continues to deliver outstanding results, reflecting solid execution across our diverse portfolio. We also enhanced our long-term growth potential by securing key regulatory approvals, generating differentiated clinical data and completing the acquisition of Apogee Therapeutics. Given our strong outlook and significant momentum, we are once again increasing AbbVie's full-year guidance and raising our quarterly dividend."

Media additions

Robert A. Michael, Chairman and Chief Executive Officer, via biospace.com

Segment performance and financial breakdown

Profit-sharing arrangements applied to both international Imbruvica revenues and U.S. And international Epkinly revenues.

Both GAAP and adjusted diluted EPS figures included an unfavorable impact of $0.11 per share stemming from acquired in-process research and development (IPR&D) and milestone expenses of $216 million on a pre-tax basis and $205 million on an after-tax basis for the three months ended 30 September 2026. This compared with an unfavorable impact of $1.50 per share in the same period of the prior year.

For the nine months ended 30 September 2026, cumulative acquired IPR&D and milestone expenses totaled $1.3 billion on a pre-tax basis and $1.2 billion on an after-tax basis, representing an unfavorable impact of $0.69 per share. The company also recorded intangible asset impairments of $847 million related to Resonic and Durysta intangible assets during the year.

Guidance revisions and dividend commitment

Bolstered by third-quarter results, AbbVie raised its full-year 2026 adjusted diluted EPS guidance range to between $13.95 and $13.99, up from the previous band of $13.76 to $13.96. Management noted that the updated guidance explicitly incorporates the $0.69 per share negative impact from acquired IPR&D and milestones incurred year-to-date through the third quarter, while excluding any potential impact from such items beyond the third quarter due to forecasting unpredictability.

Reflecting confidence in ongoing cash flow sustainability, the board of directors declared an increase in the quarterly cash dividend. The payout rises from $1.73 to $1.82 per share, representing a 5.2% increase. Since its inception in 2013, AbbVie has raised its quarterly dividend by 355%. The company maintains its status as a member of the S&P Dividend Aristocrats Index, which tracks firms with at least 25 consecutive years of annual dividend increases.

Regulatory progress and pipeline developments

The company completed its acquisition of Apogee Therapeutics.

Wider industry context

AbbVie's earnings announcement coincided with parallel updates across the biotechnology sector. Fellow industry participant OmniAb reported third-quarter revenue of $4.0 million, up from $2.2 million a year earlier, driven by its xPloration platform and service revenue on antibody and ion channel programs. OmniAb raised its full-year 2026 revenue guidance to a range of $35 million to $39 million and announced a new global collaboration with Eli Lilly and Company for an undisclosed ion channel program featuring up-front payments and potential milestones of up to $370 million.

What investors should watch next

• Dividend payment schedule: The increased quarterly cash dividend of $1.82 per share is scheduled to be paid on 16 February 2027 to shareholders of record as of 15 January 2027.
• Guidance execution: Investors will monitor whether management achieves the revised full-year 2026 adjusted diluted EPS range of $13.95 to $13.99 through the final quarter.